FibroBiologics’ (FBLG) Buy Rating Reaffirmed at D. Boral Capital

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reiterated by D. Boral Capital in a note issued to investors on Friday,Benzinga reports. They currently have a $16.00 price target on the stock.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of FibroBiologics in a research report on Wednesday, November 13th. Rodman & Renshaw began coverage on FibroBiologics in a report on Thursday, December 12th. They set a “buy” rating and a $12.00 price target on the stock. Maxim Group started coverage on FibroBiologics in a research note on Tuesday, September 24th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, EF Hutton Acquisition Co. I raised FibroBiologics to a “strong-buy” rating in a research report on Wednesday, September 4th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $13.00.

FibroBiologics Stock Performance

Shares of FBLG stock opened at $2.31 on Friday. FibroBiologics has a one year low of $1.08 and a one year high of $55.00. The firm has a 50-day moving average of $2.68 and a 200-day moving average of $3.34.

Hedge Funds Weigh In On FibroBiologics

Several institutional investors have recently bought and sold shares of FBLG. Fund Evaluation Group LLC bought a new stake in shares of FibroBiologics in the second quarter valued at $5,265,000. Cascade Financial Partners LLC bought a new stake in FibroBiologics in the 2nd quarter valued at about $1,572,000. Bank of New York Mellon Corp purchased a new stake in FibroBiologics during the second quarter valued at about $342,000. Mercer Global Advisors Inc. ADV bought a new position in FibroBiologics during the second quarter worth about $51,000. Finally, Concurrent Investment Advisors LLC purchased a new position in shares of FibroBiologics in the second quarter worth about $176,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.